Showing results (2071-2080 of 3,020) with videos related to

Sort By:
Pageof 302
Aging Cell|October 19, 2022
Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicityEleni-Dimitra Papanagnou, Sentiljana Gumeni, Aimilia D Sklirou, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2026
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal FunctionLudek Pour, Sosana Delimpasi, Wojciech Legiec, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Heart (British Cardiac Society)|March 26, 2016
Multimodality imaging in congenital heart disease-related pulmonary arterial hypertensionMichele D'Alto, Konstantinos Dimopoulos, Werner Budts, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Oncology|September 20, 2002
Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trialsC Bacoyiannis, M A Dimopoulos, H P Kalofonos, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|November 7, 2019
Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven ProcessLoula Papageorgiou, Kutaiba Alhaj Hussen, Sandrine Thouroude, et al.
British Journal of Haematology|November 22, 2018
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myelomaShaji K Kumar, Norbert Grzasko, Sosana Delimpasi, et al.
American Journal of Hematology|June 1, 1994
Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiationM A Dimopoulos, J C Yau, S D Huan, et al.
Pageof 302